Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL19260723

CCN(CC)CCCOc1cc2nc3ccccc3c(Cl)c2cc1OC.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ USP2 O75604 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ KDR P35968 5/20 0.43
▸ ACHE P22303 6/20 0.42
▸ BCHE P06276 4/20 0.42
▸ ERBB2 P04626 1/20 0.41
▸ GAA P10253 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ WHR1 P49842 1/20 0.40
▸ ABCB11 O95342 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20734756 0.91 EGFR (0.50) EGFRKDM4EALDH1A1USP2ALOX15
Trifluoroacetic Acid SCHEMBL20720787 0.91 EGFR (0.44) EGFRKDM4EACHEBCHECYP1A2
Trifluoroacetic Acid SCHEMBL19260559 0.87 KDM4E (0.45) EGFRKDM4EALDH1A1USP2ALOX15
SCHEMBL19260709 0.81 EGFR (0.49) EGFRKDM4ECYP1A2CYP2D6
Trifluoroacetic Acid SCHEMBL19260557 0.78 EGFR (0.44) EGFRKDM4EMAPK1ACHEBCHE
SCHEMBL20720752 0.77 CACNA2D1 (0.50) EGFRKDM4EALDH1A1USP2ALOX15
SCHEMBL11809733 0.74 MAOA (0.60) KDM4EALDH1A1USP2ALOX15MAPK1
Trifluoroacetic Acid SCHEMBL5929886 0.72 CSF1R (0.58) —
SCHEMBL19260666 0.71 TLR7 (0.59) —
SCHEMBL19260694 0.71 SPIN1 (0.58) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11254651-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2022-02-22 — — US disclosed
EP-3416963-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-28 — — EP disclosed
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2019-02-14 — — US disclosed
EP-3416963-A1 HISTONE METHYLTRANSFERASE INHIBITORS Global Blood Therapeutics, Inc. (US) 2018-12-26 — — EP disclosed
WO-2017142947-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2017-08-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190047981-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, BMI1 EGFR 4848/4885KDM4E 42/4885ALDH1A1 1471/4885
US-11254651-B2 Histone methyltransferase inhibitors EHMT1, EHMT2, BMI1 EGFR 4848/4885KDM4E 42/4885ALDH1A1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback